Collectively, these data suggest that the LCN2-neutralizing antibody enhanced the ferroptosis-inducing effect of sorafenib on HCC patient-derived xenograft tumors with low expression of LIFR and high expression of LCN2. The gene discussed is LIFR; the disease is hepatocellular carcinoma.